Neuphoria Therapeutics (NEUP) EBIAT (2024 - 2025)
Neuphoria Therapeutics (NEUP) has disclosed EBIAT for 2 consecutive years, with $1.9 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT rose 197.77% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.7 million, a N/A change, with the full-year FY2025 number at -$400000.0, up 97.42% from a year prior.
- EBIAT was $1.9 million for Q4 2025 at Neuphoria Therapeutics, up from -$9.9 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $11.3 million in Q1 2025 to a low of -$9.9 million in Q3 2025.